IMPORTANT NOTICE: Our email addresses will soon change. Learn more >>
Loading...

APC anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1dot2_APC_032808
PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
  • XMG1dot2_APC_032808
    PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
Compare all formats See APC spectral data
Cat # Size Price Save
505809 25 µg ¥8,470
505810 100 µg ¥24,880
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Tian WJ, et al. 2021. Clin Exp Pharmacol Physiol. 48:902. PubMed
  2. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  3. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  4. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  5. Stone ET, et al. 2022. Cell Rep. 38:110388. PubMed
  6. Guttman O, et al. 2022. J Cell Biol. 221: . PubMed
  7. Qu L, et al. 2022. Cell. 185:1728. PubMed
  8. Grebinoski S, et al. 2022. Nat Immunol. 23:868. PubMed
  9. Guo X, et al. 2022. Invest Ophthalmol Vis Sci. 63:12. PubMed
  10. Blanas A, et al. 2022. iScience. 25:104719. PubMed
  11. Gary EN, et al. 2022. Cell Rep Med. 3:100693. PubMed
  12. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  13. Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed
  14. Balood M, et al. 2022. Nature. 611:405. PubMed
  15. Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed
  16. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  17. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  18. Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed
  19. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  20. Phares TW, et al. 2022. Front Pharmacol. 13:1029636. PubMed
  21. Xiao J, et al. 2023. J Clin Invest. 133: . PubMed
  22. Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed
  23. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  24. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  25. Vijver SV, et al. 2023. Front Immunol. 13:1100730. PubMed
  26. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  27. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  28. Tao X, et al. 2022. J Exp Med. 219:. PubMed
  29. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  30. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  31. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  32. Wang Z, et al. 2022. J Control Release. 349:929. PubMed
  33. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  34. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  35. Shi X, et al. 2023. iScience. 26:106143. PubMed
  36. Tursi NJ, et al. 2023. Front Immunol. 14:1072810. PubMed
  37. Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed
  38. Latour YL, et al. 2023. Gut Microbes. 15:2192623. PubMed
  39. Mackin S, et al. 2023. Nat Microbiol. 8:569. PubMed
  40. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  41. Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed
  42. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  43. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  44. Wang X, et al. 2023. Nat Commun. 14:3440. PubMed
  45. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  46. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
  47. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  48. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  49. Chinta KC et al. 2018. Cell reports. 25(7):1938-1952 . PubMed
  50. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  51. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  52. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  53. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  54. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  55. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  56. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  57. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  58. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  59. Yang N, et al. 2022. NPJ Vaccines. 7:120. PubMed
  60. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  61. Suresh R, et al. 2020. J Immunother Cancer. 8:. PubMed
  62. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  63. Du C, et al. 2016. Nat Commun. 7: 11120. PubMed
  64. Cella M, et al. 2019. Nat Immunol. 1.513888889. PubMed
  65. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
  66. Vacca M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed
  67. Yang C, et al. 2018. J Immunol. 200:1316. PubMed
  68. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  69. Angiari S, et al. 2020. Cell Metab. 31:391. PubMed
  70. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  71. Laroche-Lefebvre C, et al. 2016. J Immunol. 197: 3618 - 3627. PubMed
  72. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  73. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  74. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  75. Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
  76. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  77. Diao L, et al. 2022. iScience. 25:105511. PubMed
  78. Guo Q, et al. 2021. Front Cardiovasc Med. 8:633212. PubMed
  79. Gu M, et al. 2021. Nat Immunol. 22:193. PubMed
  80. Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed
  81. Rao E, et al. 2021. Sci Immunol. 6:. PubMed
  82. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  83. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  84. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  85. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  86. Devalaraja S, et al. 2020. Cell. 1098:180. PubMed
  87. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  88. Zhao Y, et al. 2015. PLoS One. 10: 0134797. PubMed
  89. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  90. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
  91. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  92. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  93. Lu J, et al. 2018. ACS Nano. 12:11041. PubMed
  94. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  95. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  96. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  97. Saini V, et al. 2020. Nat Commun. 0.845138889. PubMed
  98. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  99. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  100. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  101. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  102. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  103. Konrath KM, et al. 2022. Cell Rep. 38:110318. PubMed
  104. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  105. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  106. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  107. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  108. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  109. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  110. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  111. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  112. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  113. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  114. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  115. Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed
  116. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  117. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  118. Lai C, et al. 2009. Invest Ophthalmol Vis Sci. 50:4279. PubMed
  119. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  120. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  121. Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed
  122. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  123. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  124. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  125. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  126. Mills C, et al. 2022. Cells. 11:. PubMed
  127. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  128. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  129. Marks KE, et al. 2021. Cell Reports. 35(13):109303. PubMed
  130. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  131. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  132. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  133. Harty J 2009. Infect Immun. 77:1894. PubMed
  134. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  135. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  136. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  137. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  138. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  139. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  140. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  141. Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed
  142. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  143. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  144. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  145. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  146. Bhattacharya D, et al. 2014. J Biol Chem. 289:16508. PubMed
  147. El-Zaatari M, et al. 2014. J Immunol. 193:807. PubMed
  148. Souza COS, et al. 2021. iScience. 24(6):102548. PubMed
  149. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  150. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  151. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  152. Yong L, et al. 2022. Nat Commun. 13:4255. PubMed
  153. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  154. Yuan Y, et al. 2022. Cell Rep. 38:110256. PubMed
  155. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  156. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  157. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  158. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  159. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  160. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  161. Baban B, et al. 2021. JCI Insight. 6:00. PubMed
  162. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  163. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  164. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  165. Park JY, et al. 2019. Cell Rep. 27:2548. PubMed
  166. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  167. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  168. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  169. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  170. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  171. Huang F, et al. 2018. Oncoimmunology. 7:e1450713. PubMed
  172. Levesque S, et al. 2019. Oncoimmunology. 8:e1657375. PubMed
  173. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  174. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  175. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  176. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  177. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  178. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  179. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  180. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  181. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
  182. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  183. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  184. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  185. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  186. Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed
  187. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  188. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  189. Pandit M, et al. 2021. Eur J Immunol. 51:1461. PubMed
  190. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  191. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  192. Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed
  193. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  194. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  195. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  196. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  197. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  198. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  199. Gupta S, et al. 2022. Life Sci. 288:120182. PubMed
  200. Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed
  201. Derada Troletti C, et al. 2021. Cell Reports. 35(9):109201. PubMed
  202. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  203. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  204. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  205. Jin R, et al. 2008. J Immunol. 180:2256. PubMed
  206. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  207. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  208. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  209. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  210. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  211. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  212. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
  213. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  214. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  215. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  216. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  217. M H, et al. 2016. Open Bio. 6: 150208. PubMed
  218. Moon J, et al. 2020. Immune Netw. 20:e40. PubMed
  219. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  220. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  221. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  222. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  223. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  224. Li E, et al. 2021. Front Immunol. 12:667177. PubMed
  225. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  226. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  227. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
  228. Kurihara T, et al. 2015. PLoS One. 10: e0139692. PubMed
  229. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  230. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  231. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  232. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  233. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  234. Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed
  235. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  236. Byrne K, et al. 2014. J Immunol. 192:1433. PubMed
  237. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  238. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  239. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  240. Okuyama Y, et al. 2020. FASEB J. 540:34. PubMed
  241. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  242. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  243. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  244. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  245. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  246. Yang N, et al. 2021. NPJ Precis Oncol. 5:37. PubMed
  247. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  248. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  249. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  250. Sheng J, et al. 2021. eLife. 10:00. PubMed
  251. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  252. Bransi A, et al. 2015. Cancer Immunol Res. 3: 1279 - 1288. PubMed
  253. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  254. Kwak JE, et al. 2019. Nat Commun. 10:3836. PubMed
  255. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  256. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  257. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  258. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  259. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  260. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  261. Yang L, et al. 2021. Front Immunol. 12:722273. PubMed
  262. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  263. Tang L, et al. 2022. Front Immunol. 12:770402. PubMed
  264. Kalim KW, et al. 2021. Front Immunol. 12:726393. PubMed
  265. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  266. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  267. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  268. Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed
  269. Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed
  270. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
RRID
AB_315403 (BioLegend Cat. No. 505809)
AB_315403 (BioLegend Cat. No. 505810)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
IFN-gamma
Specificity Alt (DOES NOT SHOW ON TDS):
IFN-γ
App Abbreviation (DOES NOT SHOW ON TDS):
ICFC
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account